Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
IBI110 is a monoclonal antibody that targets LAG3 on tumor infiltrating lymphocytes, and prevents the interaction between LAG3 and MHC II molecules expressed on antigen-presenting cells and tumor cells, potentially leading to increased cytotoxic T lymphocyte-mediated antitumor immune response and inhibition of tumor growth (NCI Drug Dictionary).
|DrugClasses||LAG3 Antibody 15|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|IBI110 + Sintilimab||IBI110 Sintilimab||0||0|